ArticleFrontiers in oncology2026
Bladder mucosal apoptosis index and quality of life after adjuvant intravesical BCG therapy for non-muscle-invasive bladder cancer: a retrospective propensity-score-matched study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the association of adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy after transurethral resection of bladder tumor (TURBT) with bladder mucosal apoptosis index, recurrence-related outcomes, progression-free survival, and 12-month quality of life in patients with non-muscle-invasive bladder cancer (NMIBC). Methods: A retrospective analysis was conducted on 114 NMIBC patients who underwent TURBT at our hospital from January 2022 to December 2024, including 57 patients receiving postoperative intravesical BCG immunotherapy (BCG group) and 57 patients receiving TURBT alone without postoperative adjuvant intravesical therapy (control group). Tumor recurrence rates, progression-free survival (PFS), bladder mucosal apoptosis index, and quality of life (QOL-BREF) scores were compared between groups. Results: Baseline characteristics of both groups were balanced via propensity score matching (PSM) (P>0.05). The BCG group exhibited a significantly higher bladder mucosal apoptosis index (32. 13 ± 5.61) compared to the control group (18.72 ± 4.29) (P<0.001). Six-month and one-year recurrence rates were markedly lower in the BCG group (2 cases, 3.51%; 8 cases, 14.04%) versus the control group (9 cases, 15.79%; 21 cases, 36.84%) (P<0.001), with median PFS extended to 25 months (control group: 13 months, P<0.001). Pearson correlation analysis showed a positive correlation between apoptosis index and PFS (r=0.61, P<0.001), and multivariable Cox regression further indicated that a higher apoptosis index was independently associated with a lower risk of recurrence or progression. Preoperative QOL-BREF scores showed no significant difference between groups (54. 11 ± 5.96 vs. 54.03 ± 6.27, P>0.05), while postoperative scores were significantly higher in the BCG group (71.95 ± 8.23 vs. 63.47 ± 8.22) (P<0.001). Conclusion: In this retrospective propensity-score-matched cohort, adjuvant intravesical BCG immunotherapy after TURBT was associated with a higher bladder mucosal apoptosis index, lower recurrence risk, longer progression-free survival, and better 12-month QOL-BREF scores. These findings support the clinical relevance of apoptosis index and QOL assessment in postoperative NMIBC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.